The stock of Pulmonx Corp (NASDAQ: LUNG) has increased by 11.69 when compared to last closing price of 6.16.Despite this, the company has seen a gain of 12.79% in its stock price over the last five trading days. zacks.com reported 2024-11-21 that The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is It Worth Investing in Pulmonx Corp (NASDAQ: LUNG) Right Now?
The 36-month beta value for LUNG is also noteworthy at 0.70. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LUNG is 35.82M, and at present, short sellers hold a 2.32% of that float. The average trading volume of LUNG on December 27, 2024 was 215.45K shares.
LUNG’s Market Performance
LUNG’s stock has seen a 12.79% increase for the week, with a 4.08% rise in the past month and a -16.71% fall in the past quarter. The volatility ratio for the week is 7.19%, and the volatility levels for the past 30 days are at 6.60% for Pulmonx Corp The simple moving average for the past 20 days is 8.97% for LUNG’s stock, with a -5.61% simple moving average for the past 200 days.
Analysts’ Opinion of LUNG
Many brokerage firms have already submitted their reports for LUNG stocks, with Citigroup repeating the rating for LUNG by listing it as a “Neutral.” The predicted price for LUNG in the upcoming period, according to Citigroup is $7.50 based on the research report published on December 11, 2024 of the current year 2024.
Lake Street, on the other hand, stated in their research note that they expect to see LUNG reach a price target of $12. The rating they have provided for LUNG stocks is “Buy” according to the report published on June 04th, 2024.
Wells Fargo gave a rating of “Equal Weight” to LUNG, setting the target price at $14 in the report published on February 23rd of the current year.
LUNG Trading at 6.07% from the 50-Day Moving Average
After a stumble in the market that brought LUNG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.62% of loss for the given period.
Volatility was left at 6.60%, however, over the last 30 days, the volatility rate increased by 7.19%, as shares surge +6.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.15% lower at present.
During the last 5 trading sessions, LUNG rose by +12.79%, which changed the moving average for the period of 200-days by -22.70% in comparison to the 20-day moving average, which settled at $6.31. In addition, Pulmonx Corp saw -46.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LUNG starting from Rose Geoffrey Beran, who sale 4,376 shares at the price of $6.18 back on Dec 02 ’24. After this action, Rose Geoffrey Beran now owns 291,057 shares of Pulmonx Corp, valued at $27,065 using the latest closing price.
Lehman David Aaron, the GENERAL COUNSEL of Pulmonx Corp, sale 5,497 shares at $6.19 during a trade that took place back on Dec 02 ’24, which means that Lehman David Aaron is holding 197,851 shares at $34,006 based on the most recent closing price.
Stock Fundamentals for LUNG
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.74 for the gross margin
The net margin for Pulmonx Corp stands at -0.72. The total capital return value is set at -0.38. Equity return is now at value -51.99, with -32.41 for asset returns.
Based on Pulmonx Corp (LUNG), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 0.4. The interest coverage ratio of the stock is -15.82.
Currently, EBITDA for the company is -55.09 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 3.33. The receivables turnover for the company is 6.43for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.70.
Conclusion
In summary, Pulmonx Corp (LUNG) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
